chaithanya kiran indukuru naga

Dr. chaithanya kiran indukuru naga


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ROHAN KALYAN REJROHAN KALYAN REJ
ROHAN KALYAN REJ
SASrinivasa Rao Allu
Srinivasa Rao Allu
JRJoyeeta Roy
Joyeeta Roy
RARanjan Kumar Acharyya
Ranjan Kumar Acharyya
CNchaithanya kiran indukuru naga
chaithanya kiran indukuru naga
DVDhamodharan Venugopal
Dhamodharan Venugopal
Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality that show promise to open a target space not accessible to conventional small molecules via a degradation-based mechanism. PROTAC degraders, due to their bifunctional nature, which is categorized as ‘beyond the Rule of Five’, have gained attention as a distinctive therapeutic approach for oral administration in clinical settings. However, the development of PROTACs with adequate oral bioavailability remains a significant hurdle, largely due to their large size and less than ideal physical and chemical properties. This review encapsulates the latest advancements in orally delivered PROTACs that have entered clinical evaluation as well as developments highlighted in recent scholarly articles. The insights and methodologies elaborated upon in this review could be instrumental in supporting the discovery and refinement of novel PROTAC degraders aimed at the treatment of various human cancers.